BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Solara’s Visakhapatnam Facility Achieves US FDA Compliance

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Solara's Visakhapatnam API facility passes US FDA inspection with zero observations, maintaining compliance. Spread across 40 acres, it specialises in Ibuprofen API production and key starting material, enhancing supply chain integration. Solara now has two FDA-inspected sites for Ibuprofen.

Solara Active Pharma News Today

Solara Active Pharma Sciences Limited announces the successful completion of the US Food and Drug Administration (US FDA) inspection at its multipurpose API manufacturing facility in Visakhapatnam, Andhra Pradesh.

Explore: Solara Active Pha Sci Ltd Share Price

Zero Observations Outcome

The inspection, conducted from 14th to 17th May 2024, revealed an "Acceptable State of Compliance" with zero Form 483 inspectional observations, as stated by Solara in its filing to the stock exchange.

Site Overview and Specialization

Spread over 40 acres, Solara's Visakhapatnam facility is a green field project with dedicated facilities for Ibuprofen API manufacturing. Additionally, it produces key starting materials for Ibuprofen, ensuring backward integration of the critical supply chain.

Additional Read: Share Market News

CEO's Statement

Poorvank Purohit, MD & CEO of Solara, expressed satisfaction with the inspection outcome, highlighting it as the second successful US FDA inspection at the site. He emphasised the company's commitment to maintaining the highest compliance standards across its manufacturing facilities.

Expansion and Regulatory Approvals

Solara's Visakhapatnam facility is not only focused on Ibuprofen API but is also engaged in validating other APIs for registration in various regulated markets globally. The company's six manufacturing facilities and R&D Centre have approvals from international regulatory agencies including US FDA, MFDS, EDQM, PMDA, and WHO.

Future Outlook

With this successful inspection, Solara strengthens its position as a leading API provider, ensuring business continuity and reinforcing its commitment to quality and compliance amidst evolving regulatory requirements. The company remains focused on sustaining its quality culture and further anchoring compliance efforts.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9.5 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4400+ Cr MTF Book

icon-with-text